Check Out 3 Health Care Stocks With Over 3% Dividend Yields From Wall Street's Most Accurate Analysts

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Organon & Co. OGN

• Dividend Yield: 4.97%
• Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $26 to $25 on May 8, 2023. This analyst has an accuracy rate of 65%.
• B of A Securities analyst Jason Gerberry downgraded the stock from Neutral to Underperform and slashed the price target from $37 to $25 on Oct. 14, 2022. This analyst has an accuracy rate of 70%.
• Recent News: Organon reported worse-than-expected Q1 adjusted EPS and sales results.

AbbVie Inc. ABBV

• Dividend Yield: 4.00%
• Guggenheim analyst Vamil Divan maintained a Buy rating and cut the price target from $172 to $171 on April 28, 2023. This analyst has an accuracy rate of 75%.
• Wells Fargo analyst Mohit Bansal maintained an Overweight and cut the price target from $200 to $195 on April 28, 2023. This analyst has an accuracy rate of 74%.
• Recent News: AbbVie reported Q1 adjusted EPS of $2.46, down 22.2% Y/Y, in line with the consensus.

Amgen Inc. AMGN

Dividend Yield: 3.60%

• Oppenheimer analyst Jay Olson maintained an Outperform rating and cut the price target from $292 to $290 on April 24, 2023. This analyst has an accuracy rate of 76%.
• Wells Fargo analyst Mohit Bansal upgraded the stock from Equal-Weight to Overweight and slashed the price target from $275 to $265 on March 13, 2023. This analyst has an accuracy rate of 74%.
• Recent News: Amgen reported mixed Q1 results.

Read More: Fox, Under Armour And 3 Stocks To Watch Heading Into Tuesday